Back to top

Analyst Blog

Therapeutic and diagnostic devices maker AngioDynamics (ANGO - Analyst Report) recently won a contract with HealthTrust Purchasing Group, a group purchasing organization (“GPO”) that supports roughly 1,400 hospitals. The contract will cover AngioDynamics’ vascular access products, including chronic and acute dialysis catheters.

The HealthTrust agreement became effective from October 1, and is expected to leverage AngioDynamics’ top-line growth. Per the agreement, the vascular access products to be covered by HealthTrust include DuraFlow, DuraFlow 2 and EvenMore chronic hemodialysis catheters, DuraMax chronic dialysis catheter, and the Schon XL acute hemodialysis catheter.

AngioDynamics had earlier been in similar contracts, with HealthTrust covering its peripheral vascular and fluid management offerings. Despite being able to sell off a bulk of its manufactured products, pricing pressure from the GPO could adversely affect selling prices and corresponding profitability of the company.

New York-based AngioDynamics specializes in the design, development, manufacture, and marketing of therapeutic and diagnostic devices to treat peripheral vascular disease as well as other non-coronary diseases. With a market-cap of $393.2 million, the company has approximately 1,400 employees and 7 operating locations worldwide.

We believe AngioDynamics is well positioned for sustained growth driven by strong market adoption of the NanoKnife system and its focus on interventional peripheral products. The recently concluded Navilyst acquisition in May, 2012 is expected to boost earnings by at least 8 cents in fiscal 2013.
 
However, management expects the proposed Vortex Medical acquisition to be dilutive to AngioDynamics’ reported earnings by 9 cents for fiscal 2013, as the company expects an approximate $5 million decrease in operating income along with a trivial impact on EBITDA.

In addition, AngioDynamics’ product line face strong challenges from the competitive offerings of its larger rivals such as Boston Scientific Corporation (BSX - Analyst Report) and CR Bard Inc. (BCR - Analyst Report). We are currently ‘Neutral’ on AngioDynamics, which carries a short-term Zacks #3 Rank (Hold rating).
 

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
TRIQUINT SE… TQNT 20.67 +6.52%
RF MICRO DE… RFMD 12.47 +6.04%
VASCO DATA… VDSI 14.77 +4.68%
STRATTEC SE… STRT 80.24 +3.00%
PATTERSON-U… PTEN 34.54 +2.98%